Hims & Hers Health (HIMS) is back under the microscope after its latest quarter paired a fresh net loss and subscriber decline with softer guidance, ongoing privacy lawsuits, and a closely watched partnership involving Lilly’s weight loss drugs.
Hims & Hers Health has swung from a very strong three year total shareholder return of about 164% to a 1 year total shareholder return that is down 46.6%. Recent Q3 results, softer guidance, privacy lawsuits, and the Lilly obesity drug deal have all contributed to a 7 day share price return that is down 24.1% and a year to date share price return that is down 41.0% at a recent price of US$19.73. This suggests that momentum has clearly faded as investors reassess both growth potential and legal risk.
Spot fresh momentum and potential turnarounds by lining up Hims & Hers Health against a curated 34 high quality undervalued stocks.Bulls point to rapid top line growth and the Lilly partnership. Bears focus on fresh losses, lawsuits, and weaker guidance. Which side does Hims & Hers Health’s current valuation seem to reward?
Against a last close of $19.73, the most followed narrative on Hims & Hers Health pins fair value at $171.19. This points to a steep implied discount based on that framework. According to Deep_Insights, an investor in the Simply Wall St Community who authored the narrative, the key question is whether the platform can justify this gap over time using a multi dimensional growth plan.
The thesis is not about one medication, one category or one quarter. It is about a company repeatedly following the same playbook while expanding its addressable market.
See why 85 investors see Hims & Hers Health as 88% undervalued.
Result: Fair Value of $171.19 (UNDERVALUED)
Still, privacy lawsuits and the recent subscriber decline could pressure Hims & Hers Health if legal outcomes or customer churn turn out worse than investors currently expect.
Find out about the key risks to this Hims & Hers Health narrative.
Mixed signals around Hims & Hers Health can be confusing, so move quickly. Review both the concerns and the upside, and weigh the 2 key rewards and 1 important warning sign.
You do not need to stop with Hims & Hers Health. Use the Simply Wall St screener to quickly surface fresh ideas that fit the kind of portfolio you want to build.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com